Who we are
Combinostics is a company dedicated to turn medical data into information with the goal to make diagnosis and follow-up of complex diseases more accurate and cost-effective. Our focus is on neurological diseases where brain imaging is part of the diagnostic workup. Our first application is for differential diagnostics in Alzheimer’s disease and other types of dementia. Our unique technology for image analytics and for combining image data with all other patient data is generic and we will expand to other disease areas such as Parkinson’s disease, stroke and multiple sclerosis during the next few years.
The company is founded on a strong scientific basis. We are involved in two EU-funded projects in dementia and we constantly publish papers describing clinical validation of aspects of our technology.
Our SaaS solution cNeuro, is a data driven clinical decision support tool that fits the workflow of radiologists and neurologists or other doctors specialised in memory disorders. If a patient gets a brain scan, images are uploaded for automated processing and a large number of imaging biomarkers are extracted. Using our patented disease state fingerprint technology, extracted imaging biomarkers are combined with all other data available for the patient. The patient’s data profile is then compared to data from a large number of previously diagnosed patients with known outcome, and the physician is provided with an intuitive overview that indicates which disease the patient’s data best fits to.
The system supports a stratified approach to diagnostics, where basic tests are used first and where the neurologists gets support in deciding which patients should get more extensive (and expensive) tests.
cNeuro helps physicians diagnose patients in an early disease stage. This reduces cost for healthcare due to fewer follow-up visits and less use of expensive diagnostic tests.
What we are looking for
We are looking for contacts with healthcare providers, for investors (Series A planned for Q1 2017) and for potential partners for our global expansion.